Overview

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of TAK-875, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda
Treatments:
Glimepiride